Diabetes

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Study links Actos with delayed dementia

German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.

Lilly, Yabao collaborate on diabetes

The companies will develop Lilly's glucokinase activator LY2608204.

Study links DPP-IV medication to heart failure, hospitalization

Editorial says risk is small, researchers say it could be clinically relevant.

MannKind's Afrezza approved

MannKind's Afrezza approved

By

The FDA approved the inhaled insulin last week.

Lilly, BI resubmit diabetes medication

The companies resubmitted SGLT2 inihibitor empagliflozen for FDA review. The EC approved the drug in May.

ADA trims kid A1C levels

ADA trims kid A1C levels

By

The American Diabetes Association has established an across-the-board recommendation that children 18 and younger should keep A1C levels at 7.5% or lower.

Patients paying more for diabetes medications

Patients paying more for diabetes medications

By

Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.

Lilly Q1 sales dip

Lilly Q1 sales dip

By

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

By

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed diabetes patients tripled during that same time period.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

By

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Study links patient confidence to Rx adherence

Study links patient confidence to Rx adherence

By

Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.

Louisiana sends Takeda $9-billion Actos bill

The drugmaker is accused of burying cancer risks associated with the diabetes medication.

FDA won't review Afrezza until July

The regulator has put off the inhaled insulin's PDUFA date by three months.

Boerhinger funds ADA initiative

The three-year collaboration includes $1.5 million for chronic kidney disease research.

EU may expand Tresiba indication

The new indication would mean Tresiba and Victoza could be prescribed in tandem.

EMA advisory panel backs Lilly/BI's empagliflozin

EMA advisory panel backs Lilly/BI's empagliflozin

By

The Committee for Medicinal Products for Human Use endorses the SGLT2 inhibitor. The FDA refused to approve the drug earlier this month because of manufacturing issues.

CRL stalls Lilly/BI's empagliflozin

CRL stalls Lilly/BI's empagliflozin

By

The issue: Boehringer's manufacturing site. The FDA is not asking for new clinical studies.

Regulators split difference over diabetes meds

Regulators split difference over diabetes meds

By

Spurred by a 2013 report of a possible link between drugs like Merck's Januvia and pancreatitis or pancreatic cancer, the FDA and EMA said they have not found a definitive link but will continue to collect data.

Lilly's GLP-1 contender takes a step forward

Lilly's GLP-1 contender takes a step forward

By

Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.

Merck latest rival in race to copy Lantus

Merck latest rival in race to copy Lantus

By

Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.

Diabetes lures pharma to the Gulf

Governments have been courting industry investment, reports the Wall Street Journal.

FDA takes closer look at AZ's saxagliptin

FDA takes closer look at AZ's saxagliptin

By

The regulator says a 2013 study that indicated a higher rate of heart failure compared to placebo—but not death—has prompted a second look at the diabetes medication.

Engaging mobile diabetes management

Engaging mobile diabetes management

By

A six-month pilot program at the University of Chicago improved glycemic control and engaged patients and HCPs through one key device: a mobile phone.

Sanofi muddles through 2013

Sanofi muddles through 2013

By

Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Sanofi sues to protect Lantus

The suit stalls Eli Lilly's biosimilar version of insulin glargine.

Lilly says 2014 will not be "trough year"

Lilly says 2014 will not be "trough year"

By

Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.

Email Newsletters